RxDoctor Payments Data

Christopher Shuhart, MD

Family Medicine · Seattle, WANPI 1841374550

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (48.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Radius Health, Inc. accounts for 79.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $2,442 and has fallen 95.6% since, to $108 in 2024. Among family medicine clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,850in general payments, 2019–2025

Across 16 payments — averaging $178.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$2K
  • Hologic Inc$300
  • Amgen$178
  • AstraZeneca$98
$53,196in research payments, 2019–2025

Across 23 payments — averaging $2312.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Radius Health, Inc.$53K

What the payments were for

  • Consulting fees$67524%
  • Travel & lodging$1,38949%
  • Food & beverage$78628%

General payments by program year

19
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Radius Health, Inc.12$2,274
Hologic Inc1$300
Amgen2$178
AstraZeneca1$98

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,850 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$109,105
Medicare patients
710
Services billed
1,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab21$36,819
Alendronate Sodium273$2,750
Risedronate Sodium12$1,496
Calcitonin-SalmonCalcitonin,salmon,synthetic11$352
Chlorthalidone12$284
Hydrochlorothiazide13$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$178$36,81921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →